Evidence map›Paper›PMID 35127324›Full record

ArticleInternational cancer conference journal2022

Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome.

Tomohiro Matsumoto, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Katsuhito Seki, Takayuki Yamanaka, Mako Ootaka, Hiroshi Nanjyo and 2 more

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Tomohiro MatsumotoDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Koji FukudaDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Taichi YoshidaDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Kazuhiro ShimazuDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Daiki TaguchiDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Hanae ShinozakiDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Katsuhito SekiDepartment of Cardiology, Akita University, Akita, Japan.
Takayuki YamanakaDepartment of Cardiology, Akita University, Akita, Japan.
Mako OotakaDepartment of Cardiology, Akita University, Akita, Japan.
Hiroshi NanjyoDepartment of Pathology, Akita University, Akita, Japan.
Hiroyuki WatanabeDepartment of Cardiology, Akita University, Akita, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Akita University, Hondo 1-1-1, Akita, 010-8543 Japan.
Akita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs), including cytotoxic T-lymphocyte associated antigen-4 inhibitors, and inhibitors of programmed cell death 1 and its ligand, are widely used in the treatment of several malignant tumors. Immune-related adverse events occur in two-thirds of recipients. Among them, cardiotoxicities are very rare (about 1%), albeit fatal. Pembrolizumab-induced cardiotoxicity in a patient was successfully treated with high-dose corticosteroids, and his cardiac function was maintained by adrenergic drugs and intra-aortic balloon pumping in the intensive care unit for 1 week. Cardiotoxicity with ICIs is an oncologic emergency, and should be managed in a pluridisciplinary setting involving cardiologists.

Indexed as

CardiotoxicitiesImmuno-check point inhibitorsIntensive care unitPembrolizumab

Identifiers

PMID35127324
PMCPMC8787003
OpenAlexW3217632780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.